AI-driven IP Intelligence Engine for Drug Discovery

Today, new drug development on average costs $2.6 billion and takes 10-14 years. But, for example, the global health emergency

over the spread of the deadly new coronavirus, is proving to be a crucial real-life test case for industry to aim dramatically reduce the

time it takes to create new vaccines and drugs to combat emerging pandemics. While AI technologies help to identify thousands of

new molecules that could be turned into potential medicines, it`s crucial to quickly establish the novelty of the most promising

candidates. Therefore, more than 135 million patents, 70 million journal articles, and 4 billion web pages are published creating a vast

corpus, Big Data of information that potentially needs to be searched to establish, for example, the novelty of a product, the state of

the art in the field of interest or the variety of components within complex compositions. Besides, 88% of the Big Data is unstructured

(in form of texts) and its volume increases by a staggering 62% annually, according to IDC. It leads to the main challenge: there is

simply way too much data for any human to read, analyze and understand.

Semantic Intelligence develops an AI-driven IP intelligence Engine enabling users to search, analyze and extract complex knowledge

on chemical-biological interactions in patents. Our proprietary State-of-the-art technology combines Natural Language Processing +

Machine Learning + Full linguistic data analysis + Chemical structure processing and Image Recognition, delivering novel ways by

integrating two languages: chemical structure and words, into a single semantic meaning. The target audience for this solution is

small and medium-sized life science companies, which currently have limitations in accessing expensive biochemistry databases. We

are aiming to disrupt the life science industry by delivering a low-cost solution to enable small & medium market players to create value by protecting their IP.